Revance Therapeutics Inc (RVNC)

20.10
0.10 0.50
NASDAQ : Health Care
Prev Close 20.20
Open 20.20
Day Low/High 19.95 / 20.54
52 Wk Low/High 12.54 / 42.41
Volume 42.60K
Avg Volume 180.50K
Exchange NASDAQ
Shares Outstanding 29.32M
Market Cap 576.13M
EPS -3.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Revance Releases Fourth Quarter And Full Year 2016 Results

Revance Releases Fourth Quarter And Full Year 2016 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced results for the fourth quarter and full year ended...

Revance To Participate In Upcoming Investor Conferences

Revance To Participate In Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming...

Revance Therapeutics To Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017

Revance Therapeutics To Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release fourth quarter 2016...

BELMONT Phase 2 Clinical Data To Be Presented At IMCAS World Congress 2017

BELMONT Phase 2 Clinical Data To Be Presented At IMCAS World Congress 2017

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced presentation of clinical data from the company's...

Revance Presents Clinical Data For RT002 Injectable At TOXINS 2017

Revance Presents Clinical Data For RT002 Injectable At TOXINS 2017

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced presentations of clinical data for DaxibotulinumtoxinA...

Revance Provides Clinical Milestones And Financial Outlook For 2017

Revance Provides Clinical Milestones And Financial Outlook For 2017

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today defined key 2017 clinical milestones for DaxibotulinumtoxinA for...

Revance Announces Positive 24-Week Duration Of Effect In Interim Results From Phase 2 Cervical Dystonia Trial

Revance Announces Positive 24-Week Duration Of Effect In Interim Results From Phase 2 Cervical Dystonia Trial

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced positive interim results from its U.

Revance Announces Initiation Of Subject Dosing In The SAKURA Phase 3 Clinical Program Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines

Revance Announces Initiation Of Subject Dosing In The SAKURA Phase 3 Clinical Program Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced initiation of subject dosing in the company's SAKURA...

Revance To Participate In The 28th Annual Piper Jaffray Healthcare Conference

Revance To Participate In The 28th Annual Piper Jaffray Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the 28 th Annual...

Revance To Participate In The Jefferies 2016 London Healthcare Conference

Revance To Participate In The Jefferies 2016 London Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the Jefferies 2016...

Revance Releases Third Quarter 2016 Results

Revance Releases Third Quarter 2016 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced results for the third quarter ended September 30, 2016.

Revance Announces Initiation Of Phase 2 Trial Of RT002 Injectable To Treat Plantar Fasciitis

Revance Announces Initiation Of Phase 2 Trial Of RT002 Injectable To Treat Plantar Fasciitis

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced initiation of a Phase 2 placebo-controlled trial of its...

Revance Therapeutics To Release Third Quarter 2016 Financial Results Thursday, November 3, 2016

Revance Therapeutics To Release Third Quarter 2016 Financial Results Thursday, November 3, 2016

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release third quarter 2016...

Commit To Buy Revance Therapeutics At $10, Earn 10.1% Annualized Using Options

Commit To Buy Revance Therapeutics At $10, Earn 10.1% Annualized Using Options

Investors considering a purchase of Revance Therapeutics Inc shares, but tentative about paying the going market price of $15.64/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2017 put at the $10 strike, which has a bid at the time of this writing of 55 cents.

Revance To Participate In The 2016 Wells Fargo Securities Healthcare Conference

Revance To Participate In The 2016 Wells Fargo Securities Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the 2016 Wells...

Revance Releases Second Quarter 2016 Results

Revance Releases Second Quarter 2016 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced results for the second quarter ended June 30, 2016.

Revance Therapeutics To Release Second Quarter 2016 Financial Results Thursday, August 4, 2016

Revance Therapeutics To Release Second Quarter 2016 Financial Results Thursday, August 4, 2016

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release second quarter 2016...

These 5 Stocks Are Primed for Breakouts

These 5 Stocks Are Primed for Breakouts

Here's a technical look at how to trade five stocks triggering breakout trades.

Revance Announces Completion Of Pre-Phase 3 Meeting With FDA For RT002 Injectable To Treat Glabellar Lines

Revance Announces Completion Of Pre-Phase 3 Meeting With FDA For RT002 Injectable To Treat Glabellar Lines

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced the completion of its Type B / pre-IND / pre-Phase 3...

Short Interest In Revance Therapeutics Makes 16.2% Move

Short Interest In Revance Therapeutics Makes 16.2% Move

The most recent short interest data has been released for the 06/30/2016 settlement date, which shows a 578,947 share increase in total short interest for Revance Therapeutics Inc , to 4,144,315, an increase of 16.24% since 06/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Commit To Buy Revance Therapeutics At $10, Earn 15.2% Annualized Using Options

Commit To Buy Revance Therapeutics At $10, Earn 15.2% Annualized Using Options

Investors eyeing a purchase of Revance Therapeutics Inc shares, but cautious about paying the going market price of $13.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $10 strike, which has a bid at the time of this writing of 45 cents.

Revance Appoints Industry Leader Julian S. Gangolli To Its Board Of Directors

Revance Appoints Industry Leader Julian S. Gangolli To Its Board Of Directors

Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Julian S.

Revance Therapeutics Becomes Oversold (RVNC)

Revance Therapeutics Becomes Oversold (RVNC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Revance Therapeutics (RVNC) Stock Plunging on Drug Results

Revance Therapeutics (RVNC) Stock Plunging on Drug Results

Shares of Revance Therapeutics (RVNC) are lower on heavy trading volume Tuesday after the company reported disappointing results for its new drug to treat crow's feat.

Revance Reports Results For RT001 Topical Phase 3 Trial For Lateral Canthal Lines

Revance Reports Results For RT001 Topical Phase 3 Trial For Lateral Canthal Lines

Revance to host conference call at 1:30 pm PDT (4:30 pm EDT) today